Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Hepatobiliary & Pancreatic Diseases International

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1499-3872(16)60062-0PMID 27020628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Non‐invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis

  2015cited by this paper
• Hepatic fibrosis and cirrhosis

  2015cited by this paper
• Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology

  2015cited by this paper
• Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study

  2014cited by this paper
• A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.

  2014cited by this paper
• Improved fibrosis staging by elastometry and blood test in chronic hepatitis C

  2014cited by this paper
• The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.

  2013cited by this paper
• Diagnostic potential of serum direct markers and non‐invasive fibrosis models in patients with chronic hepatitis B

  2013cited by this paper
• A Public Health Approach to Gun Violence

  2013cited by this paper
• Hyaluronic Acid: From Biochemical Characteristics to its Clinical Translation in Assessment of Liver Fibrosis

  2013cited by this paper
• Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

  2013cited by this paper
• Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results.

  2013cited by this paper
• Liver fibrosis staging through a stepwise analysis of non‐invasive markers (FibroSteps) in patients with chronic hepatitis C infection

  2013cited by this paper
• The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis

  2013cited by this paper
• Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C

  2013cited by this paper
• Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C.

  2013cited by this paper
• Would the Physicians Eventually Obsolete the Liver Biopsy for the Assessment of Liver Fibrosis?

  2012cited by this paper
• Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C

  2012cited by this paper
• A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis.

  2012cited by this paper
• Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers.

  2012cited by this paper
• The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection

  2011cited by this paper
• Assessment of new hyaluronic acid assays and their impact on FibroMeter scores.

  2011cited by this paper
• Validation of Hepascore as a Predictor of Liver Fibrosis in Patients with Chronic Hepatitis C Infection

  2011cited by this paper
• Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C

  2011cited by this paper
• Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C

  2011cited by this paper
• Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease.

  2011cited by this paper
• Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease.

  2010cited by this paper
• Circulating markers of liver fibrosis progression.

  2010cited by this paper
• Optimization and robustness of blood tests for liver fibrosis and cirrhosis.

  2010cited by this paper
• Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease

  2010cited by this paper
• Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels.

  2010cited by this paper
• Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.

  2010cited by this paper
• Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study.

  2010cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Utility of FIBROspect II to Detect Liver Fibrosis in Morbidly Obese Hispano-American Patients Undergoing Gastric Bypass

  2010cited by this paper
• The combination of a blood test and Fibroscan improves the non‐invasive diagnosis of liver fibrosis

  2009cited by this paper
• Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States.

  2009cited by this paper
• Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

  2009cited by this paper
• The use of FIBROSpect II score avoids liver biopsy in gastric bypass patients with NASH

  2009cited by this paper
• Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.

  2009cited by this paper
• Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

  2008cited by this paper
• Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

  2008cited by this paper
• Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C

  2008cited by this paper
• Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.

  2008cited by this paper
• Optimized stepwise combination algorithms of non‐invasive liver fibrosis scores including Hepascore in hepatitis C virus patients

  2008cited by this paper
• [Potential novel biomarkers for monitoring the fibrogenic process in livers].

  2008cited by this paper
• Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.

  2008cited by this paper
• FibroMeters: a family of blood tests for liver fibrosis.

  2008cited by this paper
• Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data.

  2008cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

  2007cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.

  2007cited by this paper
• European liver fibrosis (ELF) panel of serum markers can predict clinical outcome in a cohort of patients from England with mixed aetiology chronic liver disease

  2007cited by this paper
• Assessing liver fibrosis with serum marker models.

  2007cited by this paper
• European liver fibrosis (ELF) markers accurately distinguish fibrosis severity in chronic hepatitis C (CHC); An external validation study in a population-based cohort

  2006cited by this paper
• Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients

  2006cited by this paper
• Noninvasive biochemical markers of liver fibrosis.

  2006cited by this paper
• Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection.

  2006cited by this paper
• Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?

  2005cited by this paper
• A novel panel of blood markers to assess the degree of liver fibrosis

  2005cited by this paper
• Liver fibrosis.

  2005cited by this paper
• Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus

  2005cited by this paper
• Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

  2005cited by this paper
• Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.

  2005cited by this paper
• Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

  2004cited by this paper
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• Liver fibrosis -- from bench to bedside.

  2003cited by this paper
• Liver biopsy.

  2001cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Effects of eating on plasma hyaluronan in patients with cirrhosis: Its mechanism and influence on clinical interpretation

  1998cited by this paper
• Noninvasive diagnosis of hepatic fibrosis or cirrhosis.

  1997cited by this paper
• An algorithm for the grading of activity in chronic hepatitis C

  1996cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Classification of chronic viral hepatitis: a need for reassessment.

  1991cited by this paper
• Serum hyaluronic acid levels in cancer.

  1988cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper

• High-performance Distributed Feature Storage and Consumption Services in Power Grid Scenarios

  2022cites this paper
• Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients

  2021cites this paper